Liquidia (NASDAQ:LQDA) Director Caligan Partners Lp Acquires 5,300 Shares

Liquidia Corporation (NASDAQ:LQDA) Director Caligan Partners Lp acquired 5,300 shares of the stock in a transaction that occurred on Tuesday, May 19th. The stock was acquired at an average cost of $59.98 per share, for a total transaction of $317,894.00. Following the completion of the purchase, the director owned 8,138,951 shares in the company, valued at $488,174,280.98. The trade was a 0.07% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Liquidia Price Performance

Shares of NASDAQ LQDA opened at $61.77 on Thursday. The stock has a market cap of $5.49 billion, a price-to-earnings ratio of 441.25 and a beta of 0.41. Liquidia Corporation has a 52 week low of $11.85 and a 52 week high of $62.17. The company’s 50-day moving average price is $41.15 and its 200 day moving average price is $36.81. The company has a current ratio of 2.22, a quick ratio of 2.03 and a debt-to-equity ratio of 1.18.

Liquidia (NASDAQ:LQDA) last issued its quarterly earnings data on Monday, May 11th. The company reported $0.52 EPS for the quarter, beating analysts’ consensus estimates of $0.41 by $0.11. The firm had revenue of $132.87 million for the quarter, compared to analysts’ expectations of $119.44 million. Liquidia had a net margin of 7.74% and a return on equity of 46.82%. Liquidia’s revenue was up 4187.1% on a year-over-year basis. As a group, research analysts forecast that Liquidia Corporation will post 2.97 earnings per share for the current fiscal year.

Analysts Set New Price Targets

LQDA has been the topic of a number of recent research reports. Jefferies Financial Group restated a “buy” rating and issued a $60.00 target price on shares of Liquidia in a report on Monday, May 11th. Raymond James Financial restated a “strong-buy” rating on shares of Liquidia in a report on Thursday, March 5th. Weiss Ratings restated a “sell (d-)” rating on shares of Liquidia in a report on Tuesday, April 21st. Lifesci Capital upgraded shares of Liquidia to a “strong-buy” rating in a report on Thursday, March 5th. Finally, HC Wainwright upped their target price on shares of Liquidia from $55.00 to $67.00 and gave the company a “buy” rating in a report on Tuesday, May 12th. Three research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, Liquidia presently has a consensus rating of “Moderate Buy” and an average price target of $49.33.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Northwestern Mutual Wealth Management Co. purchased a new position in shares of Liquidia during the 4th quarter worth about $25,000. NewEdge Advisors LLC purchased a new position in shares of Liquidia during the 2nd quarter worth about $25,000. Skandinaviska Enskilda Banken AB publ purchased a new position in shares of Liquidia during the 3rd quarter worth about $30,000. FNY Investment Advisers LLC purchased a new position in shares of Liquidia during the 3rd quarter worth about $34,000. Finally, Covestor Ltd lifted its holdings in shares of Liquidia by 41.9% during the 4th quarter. Covestor Ltd now owns 1,216 shares of the company’s stock worth $42,000 after acquiring an additional 359 shares during the period. 64.54% of the stock is currently owned by hedge funds and other institutional investors.

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).